An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
Status:
Completed
Trial end date:
2017-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this multicenter, open-label study is to collect data on the occurrence of
important clinical safety events resulting from chronic vedolizumab (MLN0002) administration.